Dr. Martens Plc (DE:3U2)
FRANKFURT:3U2
3U2 Stock Chart & Stats
€0.73
-€0.09(-9.68%)
At close: 4:00 PM EST
€0.73
-€0.09(-9.68%)
Day’s Range― - ―
52-Week Range€0.53 - €1.11
Previous CloseN/A
Volume0.00
Average Volume (3M)406.00
Market Cap
€737.25M
Enterprise Value€943.31M
Total Cash (Recent Filing)€95.70M
Total Debt (Recent Filing)€397.10M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 28, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding967,472,960
10 Day Avg. Volume2
30 Day Avg. Volume406
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.34
Price to Sales (P/S)0.62
P/FCF Ratio2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.08Price Target Upside47.33% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€9.35M
Bulls Say, Bears Say
Bulls Say
Strong Brand And DTC ChannelDr. Martens' iconic brand plus a dual sales model (DTC and wholesale) provides durable revenue diversification. Higher-margin DTC sales improve unit economics and pricing power, supporting margin resilience and control over customer experience across markets.
High Gross Profit MarginA ~65% gross margin is a durable structural advantage for a footwear brand, giving room to absorb retail markdowns, invest in product and retail, and protect operating profit as topline stabilizes. It underpins long-term margin recovery efforts.
Strong Free Cash Flow And DeleveragingRising free cash flow and improved cash conversion provide financial flexibility to invest in DTC, product innovation, and geographic expansion. Better cash generation also enabled net debt reductions, lowering financing risk and supporting strategic execution.
Bears Say
Declining Revenue And Net Profit MarginSustained declines in revenue and a razor-thin net margin indicate structural demand or mix problems. Even with high gross margins, operating and net profitability erosion limits reinvestment capacity and weakens long-term shareholder returns absent a clear, sustained sales turnaround.
Collapse In Return On EquityA dramatic ROE decline signals collapsing capital efficiency and that invested capital is no longer generating prior returns. This reflects weaker profitability or poor leverage deployment and poses a sustained headwind to rebuilding investor returns without structural improvement.
Regional DTC Weakness And Product HeadwindsDeclines in EMEA DTC—a core market—alongside flagged issues in boots and sandals and tariff costs, point to persistent demand, product mix and cost pressures. These structural regional and product weaknesses constrain margin recovery and growth durability.
Dr. Martens Plc News
3U2 FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest stock price was €0.53 and its highest was €1.11 in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is €737.25M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is May 28, 2026 which is in 49 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on Nov 20, 2025. The company reported -€0.01 earnings per share for the quarter, the consensus estimate of -€0.01 by €0.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc does not currently pay dividends.
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is 0.06.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,472,960 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of -€0.01 in its last earnings report, expectations of -€0.01. Following the earnings report the stock price went up 0.564%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in DE:3U2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.08 (47.33% Upside)
€1.08 (47.33% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.87%
12-Months-Change
Fundamentals
Return on Equity
4.40%
Trailing 12-Months
Asset Growth
-7.19%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
3U2 Stock 12 Month Forecast
Average Price Target
€1.08
▲(47.33% Upside)
Technical Analysis
Options Prices
Currently, No data available
---